The pharmaceutical world is observing a significant shift in blood sugar therapy with the emergence of GLP-1 patches. These patches offer a potentially more comfortable alternative to subcutaneous administrations of GLP-1 receptor agonists, lessening the need for daily needle pokes. The approach delivers the compound directly through the epidermis,